Innoventric Overview
Innoventric is a structural heart medical device company engaged primarily in the development of percutaneous solutions for tricuspid regurgitation and right heart disease. The company has developed an easily deployable percutaneous functional tricuspid valve replacement that utilizes cross-caval anchoring and an innovative multi-valve design for long-lasting blood flow regulation. Innoventric is dedicated to the development of simple yet sophisticated transcatheter solutions to significantly improve the quality of life and life span of patients with structural heart disease.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Innoventric secures $28.5M to reduce medical need for surgical valve replacement and general anesthesia | CTech
Innoventric, an Israeli company specializing in transcatheter treatment for Tricuspid Regurgitation (TR), has raised $28.5 million in a Series B funding round. The investment was led by RA Capital Management and included participation from the European Investment Committee and returning investors BRM Group, JG Private Equity, and Mivtach Shamir Holdings. This funding brings Innoventrics total funding to $41 million since its inception in 2017. The companys innovative device offers a minimally invasive solution to TR by anchoring a prosthetic valve to the vena cava, simplifying the implantation process and improving patient outcomes. Innoventric has completed a first-in-human clinical trial in Europe and has received FDA clearance for an Early Feasibility Study in the U.S. The funds will be used to further clinical trials and expand regulatory approvals.
Investment
growth-positive
Israeli Medical Device Startup, Innoventric Ltd., Wins the Prestigious Horizon Europe Grant and Secures US $14M in Series A Investment
Innoventric, an Israeli start-up company, has developed the Trillium™ technology for the treatment of Tricuspid Valve Regurgitation. The company has rapidly progressed and has performed over 10 implantations of the Trillium™ technology in its European clinical trial. Innoventric holds a broad patent portfolio for the Trillium™ and other Tricuspid technologies. Recently, the company secured $14M in Series A financing, including a €2.5M grant from the Horizon Europe program. The financing round was led by a US based investor and a new European investor, with participation from previous round participants. Innoventric was acknowledged among the top 65 technology companies in the Horizon Europe program. The company is delighted by the financing round and proud of its Horizon Europe achievement.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $42.5M |
| Last funding | $28.5M |
| Stage | B |
| Rounds | 4 |
| Investors | 6 |
Team Members
7
Employees: 11-50
Web & Social Links
| Website | innoventric.com |
Locations
Golda Me'ir Street 3, Ness Ziona, Israel
Photos & Videos
No files yet
